ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

Introduction: Non-Small Cell Lung Cancer is the most prevalent type of cancer in lung cancer. Chemotherapy, radiation therapy, and other conventional cancer treatments have a low success rate. Thus, creating new medications is essential to halt the spread of lung cancer.Methods: In this study bioactive nature of lochnericine against Non-Small Cell Lung Cancer (NSCLC) was analyzed using various computational approaches such as quantum chemical calculations, molecular docking, and molecular dynamic simulation. Furthermore, the MTT assay shows the anti-proliferation activity of lochnericine.Results and Discussion: Using Frontier Molecular Orbital (FMO), the calculated band gap energy value associated with bioactive compounds and the molecule’s potential bioactivity is confirmed. The H38 hydrogen atom and O1 oxygen atom in the molecule are effectively electrophilic, and potential nucleophilic attack sites were confirmed through analysis of the Molecular electrostatic potential surface. Furthermore, the electrons within the molecule were delocalized, which confers bioactivity on the title molecule and was authorized through Mulliken atomic charge distribution analysis. A molecular docking study revealed that lochnericine inhibits non-small cell lung cancer-associated targeted protein. The lead molecule and targeted protein complex were stable during molecular dynamics simulation studies till the simulation period. Further, lochnericine demonstrated remarkable anti-proliferative and apoptotic features against A549 lung cancer cells. The current investigation powerfully suggests that lochnericine is a potential candidate for lung cancer.

No abstract

No abstract

No abstract

No abstract

No abstract

Background and Aim: Instances of chikungunya reported throughout the world in the past two decades of the present century. There is a lack of effective medicine or vaccine for chikungunya treatment. Non-structural protein, the nsP2 cysteine protease (nsP2pro) is an attractive target for inhibitors. It is a key enzyme for proteolytic cleavage of polyprotein precursors and produces functional proteins for replication and multiplication of the virus. Bioactive metabolites from Nigella sativa L; a popular spice and well-known medicinal plant, were selected for the current study against nsP2pro to search for potent non-toxic natural inhibitors of nsP2pro. Experimental procedure: Out of 54 bioactive metabolites from N. sativa 27 qualified drug likeliness properties. Virtual screening of 27 selected molecules was performed using AutoDock Vina. Top four molecules Kaempferol, (-)-Epicatechin, (+)-Catechin, and Apigenin with the least binding energy were taken for molecular docking employing AUTODOCK4. These metabolites were subjected to molecular dynamics simulation and MMPBSA, and the resilience of protein-ligand complexes had been assessed in terms of RMSD, RMSF, Rg, SASA, and hydrogen bonding. Results and Conclusions: Drug likeliness, molecular docking, molecular dynamics simulation properties, and MMPBSA analyses made clear that Kaempferol, (-)- Epicatechin, (+)- Catechin, and Apigenin all seem to be potential nsP2pro potent inhibitors and strong candidates for chikungunya virus drug development.